** Natco gets CDSCO nod for emergency use of Baricitinib tablets for COVID-19 treatment

Baricitinib in combination with Remdesivir, is used for treatment of COVID-19 positive patients, the Natco Pharma said

Drugmaker Natco Pharma has received emergency use approval for Baricitinib tablets, 1 mg, 2 mg and 4 mg strengths, from Central Drugs Standard Control Organisation (CDSCO) in India. 

Baricitinib, in combination with Remdesivir, is used for treatment of COVID-19 positive patients, a release from Natco on the approval said. 

Leave a Reply

Your email address will not be published. Required fields are marked *